AorTech International PLC Directors' Disclosures (6780C)

TIDMAOR

RNS Number : 6780C

AorTech International PLC

19 June 2019

AorTech International plc

("AorTech", the "Company" or the "Group")

Directors' Disclosures

AorTech International plc (AIM: AOR.L), the licensor of the world's leading long-term implantable biostable polymer (Elast-Eon(TM) ) and developer of medical devices utilising the key properties of Elast-Eon(TM) , makes the following disclosures pursuant to Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies in relation to Geoffrey Alan Berg (aged 63), David Muir Richmond (aged 56) and John Louis Ely (aged 68).

Mr Berg, on appointment as Non-Executive Director of AorTech, was a director of Berg Medical Limited and, during the five years prior to his appointment, had been a director of the Scottish Cardiac Society.

Mr Richmond, on appointment as Non-Executive Director of AorTech was a director of the following companies:

Blue Opal Resourcing Limited

Braidlock Limited

Culzean Medical Devices Limited

Rua Medical Devices Limited

On appointment, Mr Berg held 16,667 ordinary shares in AorTech ("Shares"), representing 0.11 per cent of the issued share capital of the Company. His holding remains the same today.

On appointment, Mr Richmond held 33,334 Shares, representing 0.23 per cent of the issued share capital of the Company. His holding remains the same today.

On appointment, Mr Ely held no ordinary shares in AorTech. His holding remains the same today.

This information was in error not included in the Company's announcement on 20 July 2018 relating to, inter alia, the appointments of Mr Berg, Mr Richmond and Mr Ely.

For further information contact:

   AorTech International plc                                            Tel: [phone] 

Bill Brown, Chairman

   Stockdale Securities Limited                                       Tel: [phone] 

Tom Griffiths/David Coaten

About AorTech:

AorTech has developed biostable, implantable polymers, including Elast-Eon(TM) and ECSil(TM) the world's leading long-term implantable co-polymers, now manufactured on their behalf by Biomerics LLC in Utah, USA. With several million implants and seven years of successful clinical use, AorTech polymers are being developed and used in cardiology and urological applications, including pacing leads, cardiac cannulae, stents and neuro stimulation devices. Devices manufactured from AorTech polymers have numerous US FDA PMA approvals, 510ks, CE Marks, Australian TGA and Japanese Ministry of Health approvals.

Elast-Eon(TM) and ECSil(TM)'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. A range of materials in a variety of application-specific formulations for use in medical devices and components are available.

In addition to the licensing of biostable polymers, AorTech is now developing medical devices utilising the key properties of its world class polymers.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

RDNEAKKPFSXNEFF

(END) Dow Jones Newswires

June 19, 2019 02:00 ET (06:00 GMT)